12 hours ago
1
aprott/iStock via Getty Images
The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss therapy Wegovy, allowing its use against metabolic dysfunction-associated steatohepatitis (MASH), a liver disorder.
The approval marks the market entry of the
English (US) ·